Biomaterial-guided regeneration represents a novel approach for the treatment of myopathies. Revascularisation and the intramuscular extracellular matrix are important factors in stimulating myogenesis and regenerating muscle damaged by ischaemia. In this study, we used an injectable collagen matrix, enhanced with sialyl Lewis X (sLe X ), to guide skeletal muscle differentiation and regeneration. The elastic properties of collagen and sLe X -collagen matrices were similar to those of skeletal muscle, and culture of pluripotent mESCs on the matrices promoted their differentiation into myocyte-like cells expressing Pax3, MHC3, myogenin and Myf5. The regenerative properties of matrices were evaluated in ischaemic mouse hind-limbs. Treatment with the sLe X -matrix augmented the production of myogenic-mediated factors insulin-like growth factor (IGF)-1, and IGF binding protein-2 and -5 after 3 days. This was followed by muscle regeneration, including a greater number of regenerating myofibres and increased transcription of Six1, M-cadherin, myogenin and Myf5 after 10 days. Simultaneously, the sLe X -matrix promoted increased mobilisation and engraftment of bone marrow-derived progenitor cells, the development of larger arterioles and the restoration of tissue perfusion. Both matrix treatments tended to reduce maximal forces of ischaemic solei muscles, but sLe X -matrix lessened this loss of force and also prevented muscle fatigue. Only sLe X -matrix treatment improved mobility of mice on a treadmill. Together, these results suggest a novel approach for regenerative myogenesis, whereby treatment only with a matrix, which possesses an inherent ability to guide myogenic differentiation of pluripotent stem cells, can enhance the endogenous vascular and myogenic regeneration of skeletal muscle, thus holding promise for future clinical use.
Introduction
The capacity of adult tissues to regenerate in response to injury stimuli represents an important homeostatic process. Nevertheless, the complete regenerative program in cases of aging, extended injury, peripheral artery disease or pathological conditions is severely affected and it is precluded by fibrotic tissue formation and consequent functional impairment. It is likely that the restricted tissue repair program under pathological conditions is due to either progressive loss of stem cell populations or to missing signals that limit the damaged tissues to efficiently activate a regenerative program (Carosio et al., 2011) . Despite major advances in medicine, current therapies do not yet allow for muscle regeneration to take place when needed. Attempts at stem cell therapy for these diseases have demonstrated experimental success; for instance, the transplantation of cultured circulating angiogenic cells (CACs) can restore perfusion in ischaemic hind-limbs (Kuraitis et al., 2011a) ; embryonic stem cells can improve function and prolong life in a spinal muscular atrophy model (Corti et al., 2010) ; and, improvement of motor function following mesenchymal stem cell transplantation was demonstrated in a model of DMD (Li et al., 2011) . Despite such promise, no optimal therapy has yet emerged, and the need for strategies to regenerate muscle remains considerable.
The limitations of stem cell therapy are partially attributed to the poor engraftment and persistence of transplanted cells (Suuronen et al., 2008) . To address this, materials are being tested as stem cell delivery vehicles for the regeneration of muscle; in particular, components of the body's extracellular matrices may be advantageous for therapeutic application because cells already have a pre-
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Injectable matrix-augmented myogenesis disposition for recognising them (reviewed in Kuraitis et al. (2012) ). Other technical challenges of stem cell therapy may include: potential requirement for co-administration of immunosuppressant drugs, time required for preparation of cells for transplantation, and unavailability of autologous cells. Therefore, as an alternative, an acellular approach to tissue regeneration has the potential to circumvent the risks and demands of these limitations. Recent studies have focused on the ability of implantable materials to augment tissue regeneration after ischaemic damage by the release of stem cell-activating growth factors (Borselli et al., 2010; Saif et al., 2010; Kuraitis et al., 2012) . Another strategy, one that does not rely on having to control the release of growth factors, may be to provide the tissue with a healthy cell-supportive environment by implanting a material that can mediate and augment the body's natural responses.
In designing such a biomaterial, it may be vital to consider the importance of vasculature and the extracellular matrix in the muscle regeneration process. Specifically, revascularisation and the provision of an adequate blood supply represent major limiting parameters for a successful therapeutic approach at regenerating muscle damaged by ischaemia (Ko et al., 2007; Grounds, 2008) . Regenerative myogenesis has been characterised by increased transcription of the myogenic regulatory factors (MRFs) MyoD, Myf5 and myogenin (Sabourin and Rudnicki, 2000) , and may be augmented by the activation and maturation of local myocyte progenitors, termed satellite cells, often identified by Pax7 expression (Parise et al., 2006) . In addition, appropriate adaptive changes in the intramuscular extracellular matrix can enhance the potential of muscle to recover and/or regenerate from damage (Kovanen, 2002) . Notably, type I collagen is the predominant component of the skeletal muscle's extracellular matrix (San Antonio and Iozzo, 2006) , and has been used for muscle cell differentiation in myoblast cell culture and in grafts (Kroehne et al., 2008) . Collectively, these findings suggest that a collagen-based material that can promote blood vessel growth may be an ideal candidate treatment for promoting skeletal muscle regeneration.
We previously reported on a type I collagen-derived matrix that contained the oligosaccharide sialyl Lewis X (sLe X ), a ligand for the receptor L-selectin . L-selectin, a receptor for sLe X , is expressed on the surface membrane of circulating angiogenic cells (CACs), and has a role in regulating their homing and adhesion (Biancone et al., 2004) . When applied in a rat model of muscle ischaemia, the sLe X -matrix increased the number of c-kit + , CXCR4 + and VEGFR2 + CACs, augmented blood vessel regeneration and restored perfusion, while not eliciting a foreign body or harmful immune response . Given the importance of vasculature and the extracellular matrix in muscle regeneration, and since the sLe X -matrix can promote neovascularisation and its composition is based on type I collagen, we hypothesised that it may possess the ability to stimulate regenerative myogenesis.
In this study, we characterised the mechanical properties of the sLe X -matrix (which may be contributing factors towards its regenerative effects), and its ability to promote differentiation of mouse embryonic stem cells into a myogenic lineage in vitro. In vivo, a mouse hindlimb ischaemia model was used to temporally investigate the ability of the sLe X -matrix to induce bone marrow and local tissue responses for myogenesis and vasculogenesis in ischaemic skeletal muscle. The results suggest that the provision of a vascularised matrix environment can promote regenerative myogenesis in ischaemic muscle, supporting the sLe X -matrix as a promising future therapy for muscle diseases.
Materials and Methods
Unless otherwise stated, all materials and reagents were obtained from Sigma-Aldrich (Oakville, Canada).
Matrix preparation
As previously described , 1 mM sLe X (Cedarlane Laboratories, Hornby, Canada) was prepared in 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) buffer, at pH 5.0, containing 1:1 (molar equivalent) crosslinking mixture of N-ethyl-N-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide (EDC/NHS; 13 mM). This mixture was subsequently mixed on ice with 1 % porcine type I atelocollagen (w/v; Nippon Ham, Tskuba, Japan) with 40 % (w/v) chrondroitin sulphate-C (CS-C; Wako Chemicals, Osaka, Japan) and thoroughly mixed, then diluted with phosphate buffered saline (PBS). The final concentration of each component was: 0.59 % collagen (w/v), 2.35 % (CS-C) and 0.1 mM sLe X . The final pH was adjusted to 7.2-7.4 using 1 N NaOH. Collagen-only matrices were prepared identically, but without sLe X in the mixture. For in vitro use, 150 μL of each matrix was evenly spread into a well of a 6-well culture plate (BD Biosciences, Mississauga, Canada) using a cell scraper, resulting in an approximate thickness of 6 mm. Materials were allowed 20 min at 37 °C to solidify. After gelation and hydration with media or PBS, the matrices display little affinity for TCPS and are easily removed. For in vivo application, materials were kept on ice and when required, 80 μL was rapidly transferred to a syringe and subsequently injected.
Compression testing
Unconfined compression tests were performed using an MTS Bionix 858 servo-hydraulic material-testing system (MTS, Bellevue, WA, USA) equipped with a 5 kg load cell. Matrices (± sLe X ) were swelled for 24 h in dPBS at 37 °C. Samples were cut using an 8 mm diameter punch, measured for thickness and placed inside of a plexiglass tank filled with dPBS for 1 h prior to testing at 37 °C. Samples were then placed between two non-porous stainless steel plates. Crosshead position and load were recorded using the Instron Wavemaker Software (version 7.0.0, Instron, Norwood, MA, USA) at a crosshead-speed of 50 %-per-minute and strained to a maximum of 20 % strain. Each material was tested with n = 5. Data were fitted to a stress-strain, 5-parameter double exponential growth model, as described (Millon et al., 2009 ):
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Injectable matrix-augmented myogenesis where σ is stress, ε is strain, and y 0 , a, b, c and d are curvefitting parameters. The elastic modulus, as a function of strain was calculated by differentiating Eqn. (1):
where σ' is the elastic (tangent) modulus, ε is strain, and a, b, c and d are curve-fitting parameters. Elastic moduli are reported in kPa for the linear elastic region of the curves, which is the slope of the fitted curve in the linear region.
Water contact angle assessment
Contact angle measurements were performed on a VCA Optima (AST Products, Billerica, MA, USA) contact angle system that relies on the deformation of drops or bubbles by gravity. The instrument equipped with a motorised syringe allows a water drop (5 µL) to be suspended from a syringe of known radius. The drop is held up initially by surface tension but soon is deformed by gravity. Matrices were swelled for 24 h in dPBS at 37 °C. Samples were cut using a 4 mm diameter punch, placed on the instrument's platform and tested immediately. Contact angle measurements were analysed using VCA Optima Image Analysis software (n = 6 for each material).
Rheology
Measurements of gelation time and viscosity were performed using a Brookfield R/S Plus Rheometer and a CC-3-50-2 R/S Spindle (Brookfield, Middleboro, MA, USA), as previously described . The maximum viscosity η max and the time required to reach η max (T max ) were recorded for collagen-and sLe X -matrices (n = 5 each).
Mouse embryonic stem cell culture D3 mouse embryonic stem cells (mESCs) were grown and differentiated as previously described (Kennedy et al., 2009) . Briefly, the cells were aggregated at a density of 4x10 4 cells/mL for 2 days in hanging drops and 5 days in non-tissue culture plates (Fisher Scientific, Ottawa, Canada). On day 7, the embryoid bodies were transferred to standard tissue culture polystyrene (TCPS) plates or tissue culture plates coated with either collagen or sLe X -matrix. At the same time, some aggregates were transferred to coverslips coated with 0.1 % gelatin (Fisher Scientific), collagen or sLe X -matrix for later immunofluorescence analysis. On day 10, the medium (Dulbecco's Modified Eagle Medium (DMEM) High Glucose + 15 % foetal bovine serum (FBS) + 1 % non-essential amino acids + 1 % pen-strip + 0.8 % beta-mercaptoethanol) was changed to a low serum formulation (DMEM-F12 + 1 % penicillin-streptomycin + 1 % N2 Supplement (Invitrogen/ Life Technologies, Burlington, ON, Canada)) and the cells were allowed to grow for 5 more days. On day 15, the cells were harvested from the tissue culture plates and fixed on coverslips. All experiments were performed in duplicate, with n = 6. RNA extraction, cDNA synthesis and quantitative PCR Total RNA was extracted from cells and tissues using the RNeasy Kit (Qiagen, Streetsville, Canada) following the manufacturer's protocol. The first strand of cDNA was synthesised from 1 mg RNA by reverse transcription using QuantiTect Reverse Transcription Kit (Qiagen). qPCR reactions were performed as previously described (Savage et al., 2009 ) using the primer sequences in Table  1 . The reactions and data analysis were performed on an Epgradien S system (Eppendorf, Hamburg, Germany) using RealPlex version 2.2 software (Eppendorf). Relative gene expression was calculated using the comparative Ct method as described previously (Savage et al., 2009) . Results for in vitro and in vivo tissue work were expressed as a ratio to b-actin and GAPDH, respectively. In vitro results were compared to results obtained on TCPS; in vivo results were compared to each animal's untreated, contralateral limb.
Western blotting
Cells were harvested for total protein extract with modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1 % NP-40, 0.25 % Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM 
Animal model
All procedures were performed with approval of the University of Ottawa Animal Care Committee, in compliance with the National Institute of Health's Guide for the Care and Use of Laboratory Animals. To investigate the endogenous bone marrow response, a green fluorescent protein (GFP) bone marrow transplantation (BMTx) was performed, as previously described (Whitman et al., 2004) . Briefly, 8-9 week-old female C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA) were irradiated with a total of 900 rads from a caesium source, delivered 3 h apart in 2 equal doses. Donor bone marrow cells ( 7×10 6 ) from a transgenic GFP mouse (C57BL/6-Tg(CAG-EGFP)10sb/J; Jackson Laboratories) were injected into the tail vein of irradiated recipient mice in a total volume of 150 μL dPBS. Six weeks after BMTx, proximal femoral arteries in left hind-limbs were ligated, as described (Limbourg et al., 2009) , using 4.0 silk thread, under 2 % isoflurane. Gastrocnemius muscles, downstream of the ligation site, subsequently received an 80 μL injection of: dPBS (n = 9), collagen matrix (n = 8), or sLe X -matrix (n = 8), using a 27-gauge needle (BD Biosciences) in 3 equivolumetric injections spaced throughout the muscle. Animals were sacrificed on day 14. To further characterise the myogenic response without the effects of a BMTx, the same procedure was performed on wild-type C57BL/6J mice without a BMTx, and animals were sacrificed on day 3 or day 10 (n = 6 for all treatments per time point). Additional age-matched, untreated animals (no ligation surgery or treatment) were sacrificed as baseline controls (n = 6).
Flow cytometry
Blood samples (~100 μL) were procured from the right saphenous veins on days 0 (pre-operative/baseline), 1, 4, 7 and 14 post-operatively. As previously described , CACs were isolated using density-gradient centrifugation on Histopaque 1077 and immediately stained with the following antibodies: antic-kit (Southern Biotech, Birmingham, AL, USA), anti-CXCR4 (BD Biosciences) and anti-flk-1 (eBioscience, San Diego, CA, USA). Cells were analysed with a FACSAria flow cytometer (BD Biosciences). Isotype, fluorochromematched immunoglobulin antibodies were used as controls. CAC expression of a particular antigen is presented as relative to its baseline value (at day 0).
Laser Doppler
Perfusion was assessed using laser Doppler pre-operatively (baseline) and on days 4 and 14, as previously described (Kuraitis et al., 2011a) . Briefly, under 2 % isoflurane, a multi-fibre needle probe (8 separate collecting fibres; Moor Instruments, Axminster, UK) was used to evaluate perfusion in both treated and untreated hind-limbs. Data are reported as perfusion indexes, calculated as a ratio of perfusion in treated:untreated hind-limbs.
Immunohistochemistry
Gastrocnemius muscles from BMTx mice were collected and fixed overnight in 4 % paraformaldehyde before paraffinisation. All samples were analysed in crosssection. Samples were de-paraffinised and hydrated with sequential washes in toluene and decreasing concentrations of ethanol. Antigen retrieval was performed using boiling citrate buffer (pH 5.6). All staining was performed in PBS containing 10 % normal horse serum (Vector Laboratories, Burlington, Canada). The following antibodies were used: anti-α-SMA (pre-diluted, Abcam, Cambridge, MA, USA), anti-GFP (1:100; Abcam), and anti-CXCR4 (1:50; Abcam). Hindlimbs from non-BMTx mice were collected and placed in OCT solution before being frozen in liquid nitrogen. Tissue sections were stained with antiactive caspase-3 antibody (1:50; Abcam), and myofibre borders were visualised using wheat germ agglutininTexas Red (Invitrogen, Burlington, Canada), following the manufacturer's protocol. For all analyses: sections were 5 μm in thickness; mounting medium with DAPI (Vector Laboratories) was used to visualise nuclei; and measurements and cell counts were determined from 6 random microscopic FOV, taken by a blinded observer with a (Oberkochen, Germany) Zeiss AxioObserver Z1 microscope and visualised with Axiovision. Counts were averaged from two blinded observers. The cross-sectional area (CSA) of arterioles was determined using Image Pro Plus.
Cytokine arrays
As previously described (Kuraitis et al., 2011a) , hindlimbs were lysed under liquid nitrogen, and cytokine arrays (Raybiotech, Norcross, GA, USA) were performed according to the manufacturer's recommendations. Custom cytokine arrays were used to analyse the protein levels of basic fibroblast growth factor (bFGF), insulin-like growth factor-I (IGF-I), IGF binding proteins-2 and -5 (IGFBP-2, -5), interleukin-10 (IL-10), L-selectin, P-selectin, stromal cell-derived factor-1α (SDF-1α), tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), tumour necrosis factor-α
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Functional assessment of treated muscle
A subset of mice that received PBS or one of the matrix treatments into the ischaemic hind-limb (n = 6 per group) were sacrificed at day 10 for functional assessment of the treated muscle. Untreated wild-type animals were included as controls. Soleus muscles were carefully isolated and maintained in a continuously oxygenated Krebs-Ringer bicarbonate buffer solution. One end of the muscle was linked to a fixed clamp and the other end to the lever arm of an Aurora Scientific Instruments (Aurora, ON, Canada) 300B actuator/transducer system. Muscles were electrically stimulated via two platinum electrodes and cross-sectional area, twitch force, maximum force, power decrease and time to fatigue were recorded as previously described (Del Prete et al., 2008) . Cross-sectional area measurements allowed for calculation of specific force values.
To assess the functional recovery of treated muscles, animals were subjected to a forced treadmill protocol. They were conditioned to the treadmill process for 1 week prior to final testing at an incline of 0º for 5 min at 5 m/s and 5 min at 10 m/s. Animals that did not maintain the treadmill speed received a shock of 0.5 mA. The maximal test of exhaustion was modified from Ferreira et al. (Ferreira et al., 2008) . In brief, the treadmill speed increased every 3 min at a rate of 3 m/min. Animals were removed from the treadmill when they could no longer manage to return to the treadmill from the shock platform. Total distance and speed at which exhaustion occurred were recorded (n = 5).
Statistical analysis
Comparisons between multiple groups were performed using a one-way analysis of variance with Tukey's posthoc test. Comparisons between repetetitive stimulation in power measurements were performed using a two-way analysis of variance with Bonferroni's post-hoc test. Comparisons between two groups were performed using a 2-tailed Student's t-test. (SPSS; IBM, Somers, NY, USA). Unless otherwise stated, values are expressed as means ± standard error. p values of < 0.05 were considered statistically significant.
Results

Mechanical properties of the matrices are similar to those of skeletal muscle
It is known that a substrate's mechanical properties (such as stiffness) are important for regulating the development and maintenance of muscle (Engler et al., 2004; Engler et al., 2006) . Therefore, the physical properties of sLe X -matrix and collagen-only matrix were tested to determine if these fell within the range considered favourable for the support of skeletal muscle. Rheological assessment revealed that the addition of sLe X to the collagen matrix did not alter the time to gelation at 37 ºC (p = 0.7; Fig. 1A ), nor did it change the viscosity of the material upon gelation (p = 1.0; Fig. 1B ). Both matrices (with and without the addition of sLe X ) displayed a gradual increase in stiffness and showed a linear stress-strain response up to 12 % strain, followed by a non-linear response (Fig. 1C) . In this linear region, the elastic modulus (σ') for the collagen matrix was 5.85 ±0.06 kPa. Incorporation of sLe X into the matrix increased the modulus to 7.51 ±0.07 kPa (p = 0.013). These moduli are similar to the range of native skeletal muscle elasticity (Engler et al., 2006) . Water contact angles were not measurable on the collagen matrix (Fig. 1D) , due to its extreme hydrophilicity and water content; however, the addition of sLe X generated areas on the matrices where contact angle was measured at 48.1° ±3.2, indicating the presence of less hydrophilic areas within the matrix (Fig.  1E ). To summarise, our mechanical analysis revealed that the elastic moduli of the matrices are similar to that of skeletal muscle.
Matrices facilitate myogenic differentiation of murine embryonic stem cells
To study the myogenic properties of the matrices, we compared the differentiation of murine embryonic stem cells (mESCs) on the sLe X -matrix versus collagen-only matrix and tissue culture polystyrene (TCPS) substrates over a period of 8 days, after 7 days of embryoid body formation. The culture of mESCs on collagen and/or sLe X -matrix increased mRNA levels for factors involved in myogenic progenitor formation, myogenic regulation, and final muscle development ( Fig. 2A-H) . Collagen matrix and sLe X -matrix increased mRNA levels of Pax3 (p < 0.03; Fig. 2C ), MHC3 (p < 0.05; Fig. 2D ), myogenin (p ≤ 0.1; Fig. 2E ) and troponin-C (p < 0.05; Fig. 2H ). Only culture on collagen matrix increased Pax7 mRNA levels (p = 0.02; Fig. 2B ) and Myf5 (p = 0.01; Fig. 2F ). Differences in mRNA were not noted for Six1 ( Fig. 2A) or MyoD (Fig. 2G ). An increase in the protein level of Pax3 in cells cultured on either matrix was detected by Western blotting (Fig. 2I) . The fusion index was greater for both matrix treatments (Fig. 2J) . Immunofluorescence staining demonstrated increased MHC protein in mESCs cultured on matrix versus TCPS (Fig. 2K-M ). These results demonstrate that the matrices enhanced skeletal myogenesis in mESCs, indicated by the upregulation of skeletal muscle markers.
Myocyte regeneration is enhanced 10 days postmatrix treatment
Regenerative myogenesis was quantified in sections of hind-limb muscle by the number of myocytes with centralised nuclei, which represent young myocytes under 1-month of age (Sun et al., 2009) . Data are reported as the percentage of myocytes with centralised nuclei (termed regenerating myocytes). At day 14, the sLe X -matrixtreated animals had 8.1-fold more regenerating myocytes, compared to PBS (p = 0.005; Fig. 3A ). To better understand the myogenic regenerative process of the ischaemic muscle in response to our treatment temporally, additional mice were evaluated 3 and 10 days after treatment. At day 3, mice did not show any differences in regenerating myocytes between treatment groups (p = 0.8; Fig. 3A-D) .
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Injectable matrix-augmented myogenesis However, at day 10, the sLe X -matrix treatment significantly increased the regenerating myocyte number by 4.5-fold compared to the PBS group (p = 0.02; Fig. 3A, E, G) .
Similarly, differences in the mRNA levels of several skeletal muscle markers in ischaemic hind-limbs were not noted between treatment groups at day 3. The exception was Pax7 (marker for skeletal muscle satellite cell), which was greatest in PBS-treated animals compared to treatment with collagen matrix (13.9-fold; p = 0.007) or with sLe Xmatrix (6.1-fold; p = 0.02; Fig. 4A ). However, at day 10, matrices induced the transcription of several myogenic factors (Fig. 4B) , compared to PBS. Specifically, treatment X -matrix (after 7 days of EB formation) and mRNA levels for several myogenic factors were measured by q-PCR, and compared to culture on tissue culture polystyrene plates (TCPS). The y-axis for all graphs represents the fold-difference relative to TCPS. (I) Pax3 protein expression in mESCs differentiated on the 3 substrates was measured by Western blot. Myocyte fusion was increased in both matrix treatments (J). (K-M) Hoechst staining (blue) and immunofluorescence staining for MHC (red) in differentiated mESCs. Scale bars = 180 μm. *p < 0.05 and † 0.05 < p < 0.1 vs. TCPS. Results are from 2 (n = 6 total per group; in duplicate for A-G) independent experiments.
Injectable matrix-augmented myogenesis with sLe X -matrix upregulated the hind-limb tissue mRNA levels of the MRFs MyoD (3.7-fold; p = 0.06), myogenin (8.1-fold; p = 0.007) and Myf5 (3.4-fold; p = 0.007), as well as Six1 (2.1-fold; p = 0.04), and the satellite cell markers Pax7 (8.5-fold; p = 0.06) and M-cadherin (3.5-fold; p = 0.01). There was a favourable trend for collagen matrix treatment to up-regulate the muscle differentiation marker MHC3 (3.2-fold; p = 0.06), the MRF Myf5 (1.6-fold; p = 0.09), and Six1 (2.3-fold; p = 0.1). Overall, both matrices increased the transcription of myogenic genes. Although no differences were detected between the 2 matrices, only treatment with sLe X -matrix resulted 
Injectable matrix-augmented myogenesis in significantly elevated levels of some of these genes compared to PBS, and only the sLe X -matrix treatment increased the number of new myocytes.
Cytoprotection is conferred by matrices
The level of ischaemia-induced apoptosis, as determined by positive staining for active caspase-3, was assessed in hind-limbs. At day 3, hind-limbs of PBS and collagen matrix treatments had 1.47-(p = 0.01) and 1.51-fold (p = 0.01) more apoptotic cells, respectively, than those treated with sLe X -matrix (Fig. 5A) . Later, at day 10, there was no longer a difference in local apoptosis between the two matrix treatments, but PBS-treated hind-limbs maintained more apoptotic cells than those which received collagen matrix (by 2.1-fold; p = 0.02) or sLe X -matrix (by 3.4-fold; p = 0.0002; Fig. 5A-D) . From day 3 to day 10, the number of apoptotic cells in sLe X -matrix-treated hindlimbs did not change (p = 0.4), but a reduction (0.6-fold) 
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Injectable matrix-augmented myogenesis was observed for collagen matrix treatment (p = 0.02). A trend for increased apoptosis (by 1.4-fold) was observed for the PBS treatment (p = 0.07).
Treatment with sLe X -matrix improves arteriogenesis and restores perfusion
The same hind-limb ischaemia model was used to assess matrix effects on vascular regeneration, but using a bone marrow transplantation (BMTx) model. We have previously demonstrated that an injectable matrix can restore perfusion to ischaemic muscle , and wanted to identify the role of bone marrowderived progenitors in this phenomenon. Bone marrow reconstitution was performed using donor bone marrow cells from a transgenic green fluorescent protein (GFP) mouse, so that the mobilised bone marrow cells could be tracked using immunohistochemistry and flow cytometry. Laser Doppler analysis demonstrated that the ligation surgery reduced perfusion in the hind-limb by approximately 50 %. Four days after ligation surgery and treatment injection, there was no difference in perfusion among the treatment groups ( Fig. 6A ; p = 0.6). At day 14, sLe X -matrix treatment restored perfusion to a level that was 85 % greater than the PBS group (p = 0.01), and 24 % greater than the collagen matrix group (p = 0.03; Fig. 6A ).
Although hind-limb arteriole density (determined by immunofluorescence with α-smooth muscle actin (SMA)) did not differ between matrix treatments (p = 0.7), it was increased in both the sLe X -matrix and collagen matrix groups by 1.8-(p = 0.01) and 1.7-fold (p = 0.01), respectively, compared to PBS treatment ( Fig. 6B-E) . Upon examination of arteriolar size, the mean cross-sectional area of arterioles of sLe X -matrix-treated animals was 3.2-and 5.2-fold greater than that of the collagen matrix (p = 0.01) and the PBS-treated animals, respectively (p = 0.003; Fig.  6F ). A trend for increased arteriolar area by 1.6-fold was observed for treatment with collagen matrix compared to PBS (p = 0.08). To summarise, the sLe X -matrix induced the formation of arterioles of greater size, accompanied by a greater restoration of blood flow.
The sLe X -matrix mobilises CACs from bone marrow Marrow-derived progenitor cells (GFP + cells) that were mobilised to the circulation were characterised by flow cytometry using antibodies for the CAC markers c-kit, flk-1 and CXCR4. At early time points after intramuscular delivery of the treatment (days 1-4), the sLe X -matrix increased GFP + c-kit + cells in the circulation by 1.4-fold, compared to PBS ( Fig. 7A ; p = 0.001). Both collagen and sLe X -collagen matrices increased the frequency of GFP + flk-1 + cells by 2.1-and 2.3-fold, respectively ( Fig.  7A ; p = 0.03, 0.006). At later time points (days 7-14), continued effects of the sLe X -collagen matrix treatment on bone marrow cell mobilisation were observed (Fig.  7A) . Specifically, the sLe X -matrix treatment increased circulating GFP + CXCR4 + cells compared to both PBS (1.7-fold; p = 0.04) and collagen matrix (1.5-fold; p = 0.02) treatments. In addition, sLe X -matrix treatment increased GFP 
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Matrix treatment increases marrow-derived and local CXCR4 + cell recruitment to the ischaemic hindlimb Following bone marrow cell mobilisation into the circulation, we investigated the effect of the different treatments on recruiting mobilised GFP + cells from the circulation to the ischaemic hind-limb muscle. After 2 weeks, the sLe X -matrix treatment resulted in the greatest recruitment and engraftment of bone marrow cells in the hind-limb muscle, which was 5.6-(p = 0.004) and 2.5-fold (p = 0.02) more than the PBS and collagen matrix treatments, respectively ( Fig. 7B-E) . The collagen matrix also increased the number of engrafted GFP + cells by 2.3-fold (p = 0.02), compared to PBS (Fig. 7E) . Immunostaining did not demonstrate any GFP + cell incorporation into vasculature, nor into myocytes.
The importance of CXCR4 expression for neovascularisation has been previously shown (Grounds, 2008; Seeger et al., 2009; Borselli et al., 2010) ; therefore, we sought to characterise CXCR4 + cells in the present study. Both sLe X -matrix and collagen matrix treatments increased total counts of CXCR4 + cells in treated hindlimbs compared to PBS (Fig. 7F-I) , by 3.3-(p = 0.002) and 2.4-fold (p = 0.03), respectively. Notably, the sLe Xmatrix recruited more non-marrow derived CXCR4 + cells (by 9.2-fold; likely from the local tissue since they lack GFP expression), compared to the PBS group (p = 0.02). Therefore, recruitment/engraftment of both bone marrowderived CACs and local angiogenic cells were greatest with the sLe X -matrix treatment.
Matrix treatments augment protein levels of regenerative factors and cytokines
To explore potential mechanisms for the observed myogenic and vascular regeneration, we used a mousespecific antibody array to assess protein levels of cytokines in the ischaemic tissue in the non-BMTx model. A summary of differences in the levels of various cytokines in the hind-limb is presented in Fig. 8 (differences with p < 0.05 are indicated). Animals that received neither the ligation surgery nor an injected treatment served as baseline controls. Myogenic-mediated factors assessed included IGF-1 and IGFBPs. At day 3, the sLe X -matrix greatly increased local IGF-1 (17.9-fold vs. baseline). Similarly, IGFBP-2 and -5 levels were increased with sLe X -matrix treatment vs. all other treatments at the early time point (≥2.1-and ≥1.4-fold, respectively).
In the analysis of angiogenic cytokines, notably, only the sLe X -matrix treatment increased hind-limb VEGF levels (2.3-fold vs. baseline; ≥1.8-fold vs. other treatments). In Fig. 9 . Ex vivo analysis of explanted soleus muscle function. Power was reduced in all ligated soleus muscles, compared to wild-type controls (A). Time to fatigue was unaffected with sLe X -matrix treatment, but reduced in PBS controls and collagen matrix treatment (B). Specific force (C) and specific twitch force (D) were reduced with collagen matrix treatment. *p ≤ 0.03 vs. wild-type; **p < 0.05 for wild-type vs. all other treatments.
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Injectable matrix-augmented myogenesis addition, bFGF was upregulated in both matrix treatments early on (vs. baseline at day 3), and this upregulation was maintained later on (vs. baseline and ≥4.2-fold vs. PBS at day 10). VCAM-1 was increased for all treatments at the 3-and 10-day time point; however, matrix treatments increased VCAM-1 levels by ≥2.2-fold vs. PBS early on (day 3). At 10 days, only limbs treated with PBS had a lasting increase in the anti-angiogenic and anti-remodelling protein TIMP-2 (5.4-fold vs. baseline). Matrices promoted greater levels of IL-10 (anti-inflammatory cytokine) in the ischaemic muscle (by ≥1.8-fold), compared to PBSinjected hind-limbs. Overall, both matrices increased local anti-inflammatory and angiogenic cytokines, but the sLe X -matrix treatment had the most profound effect of increasing both myogenic and vasculogenic cytokine production.
Matrix treatment affects muscle function
For the first 8 shortenings, soleus power was reduced in all treated animals, compared to wild-type (p < 0.05; Fig. 9A ). The soleus muscle from PBS-and collagen matrix-treated mice fatigued more rapidly than wildtype soleus (51.0 ±5.7 s and 53.3 ±5.4 s vs. 71.2 ±4.2 s, respectively; p ≤ 0.03; Fig. 9B ), whereas no difference in the time to fatigue was observed in sLe X -matrix-treated muscles (64.0 ±4.1 s) compared to wild-type controls. Only treatment with the collagen matrix changed the soleus twitch and specific forces compared to wild-type controls; specific force was reduced (172.1 ±10.8 vs. 214.0 ±12.7 mM; p = 0.03; Fig. 9C ) and twitch force was reduced (25.4 ±1.4 vs. 38.9 ±4.5 mM/mm 2 ; p = 0.01; Fig.  9D ). The sLe X -matrix-treated muscles only trended towards a reduction in twitch force (p = 0.1; Fig. 9D ).
The sLe X -matrix ultimately supports in vivo functional recovery
The sLe X -matrix-treated mice that were forced to run until exhaustion were able to run significantly greater lengths, compared to PBS-and collagen matrix-treated animals (553 m vs. 401 m and 433 m, respectively; p ≤ 0.009; Fig.  10A ). Exhaustion also occurred at higher speeds for sLe Xmatrix-treated mice (31.8 m/s) vs. PBS-(25.8 m/s) and collagen matrix-treated (27 m/s) animals (p ≤ 0.02; Fig.   10B ). Differences in running abilities were not observed between PBS and collagen matrix treatments.
Discussion
The need for biomaterials to act as de novo environments in vivo for stem cell and regenerative responses has been identified (Rossi et al., 2010; Kuraitis et al., 2012) . In the present study, we demonstrated that the treatment of hind-limb ischaemia with a sLe X -collagen matrix can augment bone marrow and local cell responses, to improve neovascularisation and regenerative myogenesis of skeletal muscle. Notably, the sLe X -matrix demonstrated an inherent ability to: (1) physically mimic skeletal muscle; (2) augment pluripotent mESC differentiation towards a muscle lineage; (3) stimulate skeletal muscle regeneration; (4) augment the mobilisation and recruitment of marrowderived progenitor cells; and (5) regulate the temporal expression of cytokines involved in both the muscular and vascular regenerative processes.
The culture of mESCs on our materials as a substrate resulted in increased differentiation towards a myogenic lineage compared to the standard ESC-to-myocyte culture protocol (which uses TCPS). ESC cultures were performed to assess the matrices' inherent ability to guide pluripotent progenitors towards a myocytic lineage. At day 15, mESCs cultured on matrices expressed greater levels of Pax3 and Pax7 (myogenic progenitor marker), Myf5 and myogenin (MRFs), and MHC3 (final muscle differentiation marker) versus culture on TCPS. Therefore, culture on the matrices promoted a more efficient differentiation pathway in mESCs that produced a premyogenic progenitor population, and enhanced MRF expression and terminal differentiation. Given that ESCs are pluripotent and have the capacity to differentiate into cells of any lineage (Guan et al., 1999) , it is significant that the collagen-based matrix appears to have an inherent ability to direct mESC differentiation towards a Pax3/7 +ve progenitor population and skeletal myogenesis. The generation of Pax3/7 +ve muscle progenitor cells is noteworthy, as these cells would be valuable in replenishing the satellite cell niche (Montarras et al., 2005 ; Fig. 10 . sLe X -enhanced matrix allows for functional recovery in a unilateral model of hind-limb ischaemia. When forced to run on a treadmill, animals treated with sLe X -matrix ran significantly further (A; p ≤ 0.009) and at greater speeds (B; p ≤ 0.02) than PBS-or collagen matrix-treated animals.
D Kuraitis
Injectable matrix-augmented myogenesis Kuang et al., 2007) in therapies targeted at treating muscle diseases, and Pax3/7 induce skeletal myogenesis in stem cells (Ridgeway and Skerjanc, 2001; Seale et al., 2004) . These results suggest that the collagen-based matrices could serve a two-fold purpose: (1) to provide an injectable biomaterial for the promotion of endogenous regenerative myogenesis; and (2) to enhance and enrich populations of myogenic lineage cells for transplantation. It is known that mechanical properties of a cell's extracellular environment, and in particular the elasticity of the cell's substrate, are key regulating factors in the differentiation of cells (Engler et al., 2006) . Ex vivo, cells appear to differentiate towards phenotypes that would naturally be found on similar substrates, such as neural differentiation on very soft materials and osteogenic differentiation on very hard materials. A substrate with an elastic modulus range of 6.5-17 kPa appears ideal for maximal myotube differentiation (Engler et al., 2004) . Similarly, a range of 8-17 kPa induces a myoblast-like morphology in mesenchymal stem cells and a marked increase in the myogenic transcription factor MyoD (Engler et al., 2006) . Unstimulated skeletal muscle has a range of 10-20 kPa (Engler et al., 2006) . Although these examples used atomic force microscopy, which may overestimate the moduli values, the elasticity values of our matrices (5.85 and 7.51 kPa) obtained using compression testing are quite similar. This suggests that the matrices' elasticity may play a role in the observed myogenesis. Furthermore, the statistical difference between matrices' elastic moduli may be one of the key reasons for the increased emergence of myocytic lineages on the sLe X -matrix. It is not likely that the matrices' rheological properties contributed to the observed differences in myogenesis, since viscosity and time to gelation between the two materials were very similar. However, the addition of sLe X to the collagen matrix made regions of the material less hydrophilic. The degree of hydrophilicity is another key property for cell interaction, as slight changes in a material's hydrophilicity have been shown to have dramatic effects on cellular adhesion and spreading (Elliott et al., 2007; Derkaoui et al., 2010) , and this may be involved in the observed differences in mESC phenotypes.
Pelosi et al. have demonstrated that in wild-type mice, the onset of skeletal muscle regeneration begins around 10 days after injury (Pelosi et al., 2007) . In the present study, at 3 days post-treatment, very few regenerating fibres were apparent and we observed no differences between treatments. However, at day 10, mice treated with sLe Xmatrix displayed an increase in the number of regenerating fibres, and the same effect was observed at 14 days in the BMTx model. In parallel, the sLe X -matrix did not increase the hind-limb levels of myogenic mRNA transcripts at day 3, but at day 10 it had induced an upregulation of transcripts of genes that are known to have active roles in directing myogenesis, such as M-cadherin (Donalies et al., 1991) , Myf5 (Rudnicki et al., 1993; Gayraud-Morel et al., 2007) , MyoD (Rudnicki et al., 1993) , myogenin (Nabeshima et al., 1993), Pax7 (McGeachie and Grounds, 1987) and Six1 . Interestingly, animals receiving the PBS control demonstrated a greater abundance of Pax7 transcripts at day 3, compared to both matrices. Pax7 is indicative of skeletal precursor satellite cells, and after injury, the normal response for satellite cells is to synthesise new DNA and proliferate after 18 h, peaking at 3 days and gradually reducing afterwards (McGeachie and Grounds, 1987) . Our results suggest that PBS-treated animals experienced this phenomenon, and that matrix treatment may have delayed it. Despite this delay, the sLe X -matrix was superior in inducing regenerative myogenesis over the longer term.
In our previous report, we noted that the sLe X -matrix could increase the number of CACs in the circulation . In the present study, using a GFP + marrow transplant and hind-limb ischaemia model, we demonstrated that c-kit + , flk-1 + and CXCR4 + CACs were increased in animals with sLe X -matrix-treated hindlimbs at early time points (days 1-4) after treatment. The circulating cells analysed were positive for GFP expression, indicating bone marrow origin of the responding cells. Greater numbers of these cells persisted in the circulation of sLe X -matrix-treated animals by 2 weeks post-application. The analysis of hind-limb tissue sections revealed that the sLe X -matrix was superior at recruiting marrow-derived (GFP + ) and CXCR4 + cells to the treated muscle tissue. Notably, the number of CXCR4 + cells of non-marrow origin (GFP -) was greater in hind-limbs treated with sLe Xmatrix than in the other groups, suggestive of an enhanced local cell response with this treatment. It is well-known that marrow-derived CACs are therapeutic and may augment reperfusion (Abdel-Latif et al., 2007) . Recently, the role of CXCR4 + fractions of CACs has been highlighted (Seeger et al., 2009 ): compared to CXCR4 -fractions, CXCR4 + cells display a more potent ability to migrate, as well as a superior ability to augment neovascularisation and to secrete pro-vasculogenic cytokines. This suggests that CXCR4 + cells are a highly therapeutic fraction of CACs with a strong homing ability, which is particularly important in the response to ischaemic damage and support of neovascularisation.
By 2 weeks, the sLe X -matrix improved the perfusion of ischaemic hind-limbs compared to PBS and collagen matrix treatments, although both matrices increased hindlimb arteriole density to similar levels. In contrast, we have previously observed increased arteriole density with sLe X -matrix compared to collagen matrix treatment . Despite being another hind-limb ischaemia model, there were key differences between the current study and our 2009 study that may have altered the physiological responses to the material's application: rat versus mouse model; BMTx versus non-BMTx; young (rats) versus older (mice). In this study, the sLe X -matrix was able to induce the formation of arterioles of greater size, possibly contributing to greater blood flow. This may be indicative of more mature and/or strengthened arterioles, since the size (cross-sectional area) in newly developing vasculature was recently shown to increase over time, up to a period of 4 weeks (Ruvinov et al., 2011) . The differentiation of GFP + marrow-derived cells into cells of the vasculature was not observed. The differentiation of CACs into vascular cells is a topic of intense debate (Klein et al., 2010) and the potential for vascular transdifferentiation of CACs is not yet clear. It is more likely that the increased engraftment of
Injectable matrix-augmented myogenesis GFP + marrow cells in the sLe X -matrix treated hind-limbs contributes to a greater paracrine mechanism (higher levels of angiogenic cytokines were observed), which then induces a superior local cell response (supported by the observation that greater numbers of non-marrow derived (GFP -) CXCR4 + cells were present in sLe X -matrix treated muscle). Furthermore, it was recently highlighted that the expression of L-selectin (the receptor for sLe X ) greatly enhances the in vivo migration and retention of transplanted cells into ischaemic myocardium (Bernal et al., 2011) . Therefore, the presentation of sLe X may also contribute to the retention of therapeutic cells in the ischaemic muscle.
A time course analysis of cytokines indicated the simultaneous signalling for vascular and muscular regeneration and also corroborated the myogenic and vasculogenic results that were observed. IGF-1, a potent initiator of skeletal myogenesis (Pelosi et al., 2007) , displayed the greatest increase with sLe X -matrix treatment at day 3 post-treatment. Similarly, an increase in IGF binding proteins IGFBP-2 and -5, in response to sLe Xmatrix treatment, was observed only at the 3 day time point. The family of IGFBPs (1 through 5) have implicated and overlapping roles in regulating myogenesis (Duan et al., 2010) ; however, a knock-out of multiple members has shown reduced skeletal muscle size, implicating their role in the growth and homeostasis of skeletal muscle (Ning et al., 2006) . IGFBP-5 is perhaps the most potent family member for myogenesis. Its expression increases greatly in differentiating myoblasts (Bayol et al., 2000) and in the presence of IGF-1, it can augment the myogenic actions of IGF-1, indicated by greater myogenin expression and fusion of myoblasts into myotubes (Ewton et al., 1998; Musaro and Rosenthal, 1999) . Vasculogenic cytokines were also assessed. The matrix-induced production of bFGF, a molecule able to stimulate reperfusion of ischaemic muscle (Boodhwani et al., 2008) , was observed at the same time when matrices demonstrated improved perfusion, while concurrently, the level of an inhibitor of angiogenesis, TIMP-2 (Koike et al., 2003) , was reduced. Another indicator of neovascularisation, VCAM-1 (Martin et al., 2005) , was also increased with matrix treatment. Together, with the transcriptional and morphological evidence of myogenesis, it is believed that sLe X -matrix induced local paracrine signalling, which is responsible for the later initiation of regenerative events that manifest as amplified vasculogenesis, followed by myogenesis, at around 10 days. This concept is supported by findings which demonstrate that when vascularisation is present, there is a greater functional enhancement of regenerating muscle (Koffler et al., 2011) .
PBS treatment led to the greatest local level of SDF-1 (at the late time-point), a chemoattractant for CXCR4-expressing cells. Interestingly, more CXCR4 + cells were observed in the circulation and engrafted into muscle after matrix treatment, despite the greater concentration of SDF-1 in the PBS-treated hind-limbs (at 10 days). Greater levels of SDF-1 were expected with matrix treatment; however, serum SDF-1 levels were not measured. If elevated, serum SDF-1 could explain the increase in mobilised and engrafted CXCR4 + CPCs in matrix-treated tissue. Furthermore, local SDF-1 expression in response to ischaemic injury is maintained over longer periods in older mice (~18 months) compared to the response in younger mice (3 months), which peaks at day 3 (Wang et al., 2011) . This suggests that increased SDF-1 levels may persist in tissue that is less efficient at recovering from perfusion defects; under this scenario, the PBS-treated hind-limb muscle, in which perfusion was not restored, would maintain an elevated local SDF-1 concentration compared to the re-perfused matrix-treated hind-limbs. Also, SDF-1-CXCR4 responses may not be linear, whereby a threshold concentration of SDF-1 is reached, resulting in a plateau of the CXCR4 response (Kimura and Tabata, 2010) , and therefore the elevated SDF-1 levels seen with PBS treatment may be ineffective at activating CXCR4 + cells over the long-term. Other chemokines, such as VEGF, were upregulated with sLe X -matrix treatment. When VEGF, known as a progenitor cell activator and homing factor, and as an angiogenic cytokine, is produced locally by transplanted muscle-derived stem cells, enhanced myogenesis occurs in addition to increased angiogenesis (Deasy et al., 2009) , underscoring the importance and role of local VEGF production in injured muscle. Furthermore, both matrix treatments augmented the level of IL-10, a known cytoprotective cytokine that is endogenously upregulated after an ischaemic episode (Hayward et al., 1997; Frangogiannis et al., 2000) . IL-10 has also recently been associated with improved muscle regeneration, based on its ability to inhibit the cytotoxic M1 macrophage phenotype (Villalta et al., 2011) . We assessed the potential of these materials to elicit a harmful inflammatory response by monitoring TNF-α. Similar to our previous study, the matrix application did not induce TNF-α expression , highlighting the material's biocompatibility.
It is known that ischaemic injury reduces the maximal forces in soleus muscle (Vignaud et al., 2010) and that this leads to fibre death and subsequent regeneration. Power measurements showed that all ischaemic solei were less efficient; however, the small changes in maximal (specific and twitch) forces observed in our model were surprising, but perhaps attributable to the relatively mild degree of ischaemia that was induced. Statistically, both matrix treatments reduced specific maximal forces, but the reductions observed with sLe X -matrix were less severe when compared to control animals. Despite these reductions in matrix-treated solei, it has been shown that regenerating soleus muscle exhibits reduced maximal forces, compared to soleus in a non-regenerative state (Esposito et al., 2007) , suggesting regeneration is occurring in matrix-treated muscles. Given that ischaemic injury initiates major changes in ECM composition (Roy et al., 2006) , together with the observed changes in ECMmodulating proteins in this study and others Kuraitis et al., 2011b) , we believe that muscle regeneration and ECM turnover leads to the observation of reduced maximal forces. Moreover, the reduction in specific force is probably due to the fact that the matrix increases the number of regenerating fibres, which do not contribute to force generation. We can envision that the regenerating fibres, once they complete the maturation program, will significantly contribute to an increase in
Injectable matrix-augmented myogenesis muscle strength. Despite the loss of force, this did not translate into reduced function in vivo for mice with ischaemic hind-limbs treated with sLe X -matrix, which experienced improved mobility (ran further and faster on a treadmill). Arguably the most important parameter measured, sLe X -matrix treatment allowed for functional restoration of ischaemic hind-limbs. This result was supported by the ex vivo observation that sLe X -matrix treatment improved muscle endurance, compared to both PBS-and collagen matrix-treated muscle, which reached fatigue sooner. Furthermore, these functional benefits were observed in ischaemic soleus muscles, which are distal to the injury/treatment site (gastrocnemius muscle), highlighting the potential of the matrix to mediate vascular and muscle regeneration beyond the site of application.
In order to achieve maximal recovery of skeletal muscle from ischaemic injury, the formation of new vessels is a requirement before the regeneration of myocytes will occur (Ko et al., 2007; Grounds, 2008) . Experimentally, it has been demonstrated that skeletal myogenesis is correlated with vascular regeneration after stem cell transplantation (Shi et al., 2009 ). Our study also shows that while two matrix treatments both induce relatively similar amounts of myogenesis, the treatment with superior vasculogenesis (sLe X -matrix) is the only one to lead to functional recovery in ischaemic hind-limbs. One study has used an injectable alginate scaffold to release multiple regenerative growth factors in an attempt to restore skeletal muscle after ischaemic injury (Borselli et al., 2010) . Although a combined result of muscle and vascular regeneration occurred, the outcome depended greatly on the ability of the materials/releasing systems to function properly and this function is difficult to assess in vivo. Growth factor delivery strategies face various biological, engineering and technical limitations (Chen et al., 2010) , such as loss of bioactivity, insufficient gradients and rapid cytokine depletion. Our results present an efficacious method of restoring both muscular and vascular profiles of skeletal muscle, overcoming the potential limitations that have been associated with material functionality after implantation.
Conclusions
We have presented evidence for the reperfusion and both phenotypic and functional regeneration of muscle damaged from an ischaemic event after the application of a sialyl Lewis X -enhanced injectable collagen matrix. Based on its mechanical properties and its ability to guide pluripotent cells towards a myogenic lineage, we believe that this injectable matrix has an inherent ability to support muscle regeneration. Considering the limited success of regenerative stem cell transplantation, the need for cell-free methods of regeneration may be necessary, and the non-invasive application of biocompatible, naturally derived materials that can augment neovascularisation and myogenesis holds great promise as a future therapy for prevalent myopathies.
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Injectable matrix-augmented myogenesis (age, strain, and variation in the exercise protocol) may affect the performance on a treadmill test, we prefer to not make the comparison. Ultimately, we were able to show that the sLeX-collagen matrix is the only treatment that allows for a significant functional recovery and we identify this phenomenon in the last paragraph by discussing the need for reperfusion in order for muscle regeneration to occur (which appears to only occur with sLeX-collagen matrix).
Reviewer III: While the addition of sLeX resulted in greater mobilisation of CXCR4+ cells it is unclear what role they played in the response. Would you estimate that they were more involved in the neovascularisation observed or the development of nascent muscle fibres? If they were more involved in fibre development, do you anticipate that animals allowed to recover for longer would see further improvement in function as the fibres matured and do you intend to measure this? Authors: Given that CXCR4 expression confers greater potential for angiogenesis and paracrine secretion (Seeger et al., 2009, text reference) and that neovascularisation precludes muscle regeneration, we believe that the role of the mobilised CXCR4+ cells was primarily to restore perfusion. Therefore, fibre development is dependent upon neovascularisation. In our study, perfusion was restored with sLeX-matrix treatment by 2 weeks, but molecular evidence (cytokines and transcripts) indicate that myogenesis is still on-going at this point. We cannot predict if there will be a greater functional improvement if recovery were to be assessed at a later time point, but we believe that the new fibres would be better developed at such a later time. Future studies will assess this. After the myogenic response has reached its plateau, we would expect to see reversal of the increased molecular marker expression back towards baseline levels and also increased muscle strength when muscles are analysed ex vivo.
Reviewer III: Presumably upon implantation these matrices will eventually be remodelled by the cells in the patient. Do you think there would be any differences in the remodelling response between the collagen vs. sLeX matrices that has or could add to the beneficial effects of the treatment? Authors: Two weeks after their application, physical evidence of the matrices themselves was not apparent. The turn-over time would be highly dependent upon the individual's metabolism and responses, and also the amount of material implanted -an increased bolus would take longer to be turned over. In contexts where turn-over is already completed by the study's termination, any differences in remodelling would be sustained from earlier changes induced by the matrices. While we could not specifically evaluate turn-over of our matrices in vivo, we did demonstrate in vitro that the sLeX-collagen matrix had a superior elastic modulus. Although not fully understood, there is evidence of a relationship between the elastic modulus and the turnover of extracellular matrix proteins in tendons and skeletal muscle (Kjaer, 2004; Birch, 2007, additional references) . Therefore, it is conceivable that the observed difference in elastic moduli for the 2 matrices may have been a factor in altering the remodelling response, ultimately resulting in greater functional recovery in sLeXcollagen matrix treated hind-limb muscles.
Reviewer IV: The chemical coupling reaction using a mix of proteins, glycosaminoglycans and two cross-linking agents will lead to a mixture of thousands of polymers. I wonder if the laboratories involved have made attempts to characterise them both, at the chemical as well as at the biological level and compared them to what is found in cell membranes of, for example, endothelial cells. Authors: We agree that there will be a mixture of polymers present (both major and minor products) with the major product(s) being: (1) a collagen hydrogel containing amide bonds, and (2) a collagen-chondroitin hydrogel. Separation of each polymer is difficult and even if one could separate the polymers, an NMR on every single polymer (both major and minor) would be very time consuming and expensive. If our product had been a small molecule, characterisation would be much easier. Since the materials have not been characterised, it is not possible to say if their characteristics are identical to those of the polymers produced endogenously.
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